Insights from 2023 ASH Annual Meeting

 

Insights from 2023 ASH Annual Meeting
M

RRMM: Effects of Ide-Cel vs. Standard Regimens on HRQoL in Patients Who Had Received 2-4 Prior Regimens - Updated Results From KarMMa-3

By Insights from 2023 ASH Annual Meeting FEATURING Michel Delforge
By Insights from 2023 ASH Annual Meeting FEATURING Michel Delforge
0 views
January 8, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

19:28
Agios

Pyruvate Kinase Deficiency: Clinical Manifestations and Treatment Ap…

Feat. K. Yotsumoto Fertrin
Myeloma
17:13
Insights from 2023 ASH Annual Meeting

Updates From ASH: The Evolving Role and Sequencing of Bispecifics an…

Feat. A. Jakubowiak
08:11
Insights from 2023 ASH Annual Meeting

Triple-Class-Exposed R/R MM: Results From the KarMMa-3 Trial of Ide-…

Feat. K. Patel
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
04:30
Insights from 2023 ASH Annual Meeting

High-Risk NDMM: KarMMa-2 Extended Follow-Up - Ide-Cel in HR-NDMM Pat…

Feat. M. Alsina
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
19:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…

Feat. P. Richardson
06:44
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Sonrotoclax Combined With Dexamethasone for…

Feat. H. Quach
06:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Selinexor and Lenalidomide vs. Lenalidomide…

Feat. H. Quach
05:03
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Teclistamab in R/R MM - A Multi-Institution…

Feat. R. Chakraborty
15:13
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Mezigdomide + Dex + Dara or Elo in Pts With…

Feat. P. Richardson
09:05
Insights from 2023 ASH Annual Meeting

RRMM: Effects of Ide-Cel vs. Standard Regimens on HRQoL in Patients …

Feat. M. Delforge
09:39
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Impact of Dex Dose Strength on Outcomes in …

Feat. R. Banerjee
04:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Early Peripheral Blood MRD Status by NGS in…

Feat. B. Derman
06:19
Insights from 2023 ASH Annual Meeting

Dara-KRd in NDMM Without ASCT: Final Analysis of a Ph2 Trial

Feat. B. Derman
12:32
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Early Benefits and Psychological Effects of…

Feat. S. Rögnvaldsson
10:03
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MGUS and the Risk of Thrombotic Events - Re…

Feat. S. Rögnvaldsson
10:53
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "RVd vs. RVd Plus ASCT in African Americans …

Feat. J. Zonder
17:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …

Feat. A. Jakubowiak
08:36
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Standard- and High-Risk ND Transplant-Eligi…

Feat. N. Joseph
10:06
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outcomes After CAR-T in MM Patients With Ex…

Feat. D. Pan
06:14
Insights from 2023 ASH Annual Meeting

Multiple Myeloma: Inflammatory Biomarkers and Outcomes CAR T-Cell Th…

Feat. D. Pan
12:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "GMMG ReLApsE Trial - Salvage Auto Transplan…

Feat. M. Bärtsch
10:23
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "iStopMM Study - Revised Definition of Free …

Feat. T. Einarsson Long
07:27
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Dual Targeting of SLAMF-7 and CD38 - A Ph2 …

Feat. B. Dhakal
03:14
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MyDRUG Sub-Protocol Y3 Results - Selinexor,…

Feat. J. Richter
08:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outpatient Management of CAR-T and Bi-Speci…

Feat. R. Bansal
12:03
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Daratumumab Monotherapy in Newly Diagnosed …

Feat. E. Kastritis
22:14
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "RW Safety & Efficacy of Teclistamab for…

Feat. D. Dima
09:22
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "DREAMM-6 Trial Arm-A - Belantamab Mafodotin…

Feat. R. Popat
14:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MonumenTAL-1 Study - Talquetamab in Pts Wit…

Feat. A. Jakubowiak
06:06
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "BMS-986393 (CC-95266), an Autologous GPRC5D…

Feat. S. Bal
04:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "iStopMM Study - Risk Factors of Smoldering …

Feat. S. Thorsteinsdottir
07:20
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Daratumumab, Bortezomib, Lenalidomide, and …

Feat. O. Nadeem
10:36
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Immuno-PRISM Study of Bispecific Antibodies…

Feat. O. Nadeem
11:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "CENTAURUS Study Final Analysis - Efficacy &…

Feat. O. Landgren